JP2024504377A5 - - Google Patents
Info
- Publication number
- JP2024504377A5 JP2024504377A5 JP2023544331A JP2023544331A JP2024504377A5 JP 2024504377 A5 JP2024504377 A5 JP 2024504377A5 JP 2023544331 A JP2023544331 A JP 2023544331A JP 2023544331 A JP2023544331 A JP 2023544331A JP 2024504377 A5 JP2024504377 A5 JP 2024504377A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- modified oligonucleotide
- modified
- nucleosides
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163140674P | 2021-01-22 | 2021-01-22 | |
| US63/140,674 | 2021-01-22 | ||
| US202163217624P | 2021-07-01 | 2021-07-01 | |
| US63/217,624 | 2021-07-01 | ||
| US202163231559P | 2021-08-10 | 2021-08-10 | |
| US63/231,559 | 2021-08-10 | ||
| PCT/US2022/013323 WO2022159712A1 (en) | 2021-01-22 | 2022-01-21 | Compounds and methods for reducing dux4 expression |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024504377A JP2024504377A (ja) | 2024-01-31 |
| JP2024504377A5 true JP2024504377A5 (enExample) | 2025-01-24 |
Family
ID=82549881
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023544331A Pending JP2024504377A (ja) | 2021-01-22 | 2022-01-21 | Ｄｕｘ４の発現を低減するための化合物及び方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20240336915A1 (enExample) |
| EP (1) | EP4281084A4 (enExample) |
| JP (1) | JP2024504377A (enExample) |
| WO (1) | WO2022159712A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202100928QA (en) | 2018-08-02 | 2021-02-25 | Dyne Therapeutics Inc | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
| EP4370678A2 (en) * | 2021-07-14 | 2024-05-22 | Mirecule, Inc. | Oligonucleotides and compositions thereof for neuromuscular disorders |
| JP2025532127A (ja) | 2022-09-23 | 2025-09-29 | アイオーニス ファーマシューティカルズ， インコーポレーテッド | Ｍｅｃｐ２発現を低減する化合物及び方法 |
| EP4590308A2 (en) * | 2022-09-23 | 2025-07-30 | Ionis Pharmaceuticals, Inc. | Compounds and methods for reducing mecp2 expression |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2596977T3 (es) * | 2010-09-02 | 2017-01-13 | Université de Mons | Agentes útiles en el tratamiento de la distrofia muscular facioescapulohumeral |
| EP2736539B1 (en) * | 2011-07-25 | 2017-08-23 | Nationwide Children's Hospital, Inc. | Recombinant virus products and methods for inhibition of expression of dux4 |
| US10538763B2 (en) * | 2015-01-16 | 2020-01-21 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulation of DUX4 |
| US20180237775A1 (en) * | 2015-09-21 | 2018-08-23 | Association Institut De Myologie | Antisense oligonucleotides and uses thereof |
| WO2019060432A2 (en) * | 2017-09-19 | 2019-03-28 | Children's National Medical Center | GAPMERS AND METHODS OF USING THE SAME FOR THE TREATMENT OF MUSCLE DYSTROPHY |
| WO2019157531A1 (en) * | 2018-02-12 | 2019-08-15 | Ionis Pharmaceuticals, Inc. | Modified compounds and uses thereof |
| WO2020172559A1 (en) * | 2019-02-22 | 2020-08-27 | Ionis Pharmaceuticals, Inc. | Compounds and methods for reducing atxn3 expression |
| WO2020203880A1 (ja) * | 2019-03-29 | 2020-10-08 | 田辺三菱製薬株式会社 | Ｄｕｘ４の発現を調節するための化合物、方法及び医薬組成物 |
-
2022
- 2022-01-21 US US18/262,438 patent/US20240336915A1/en active Pending
- 2022-01-21 EP EP22743253.1A patent/EP4281084A4/en active Pending
- 2022-01-21 JP JP2023544331A patent/JP2024504377A/ja active Pending
- 2022-01-21 WO PCT/US2022/013323 patent/WO2022159712A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024504377A5 (enExample) | ||
| JP2020193199A5 (enExample) | ||
| JP2022515193A5 (enExample) | ||
| JP2021530204A5 (enExample) | ||
| JP2022520986A5 (enExample) | ||
| JP2024539596A5 (enExample) | ||
| TWI881004B (zh) | 用於治療ｈｂｖ之靶向ｈｂｖ的治療性寡核苷酸及ｔｌｒ７促效劑之醫藥組合 | |
| JPH07300493A (ja) | ２′−エーテル基を有する、ヌクレオシド及びオリゴヌクレオチド | |
| TW201803989A (zh) | 拮抗ｂ型肝炎病毒之組成物和藥劑及彼等之用途 | |
| JP2023537798A5 (enExample) | ||
| JP2007523943A (ja) | 医薬組成物 | |
| JP2022518929A5 (enExample) | ||
| JPH11511014A (ja) | 免疫刺激応答が低減した遺伝子発現の調節法 | |
| JP2021072862A (ja) | Ｂ型肝炎感染の治療用のＰＡＰＤ５及びＰＡＰＤ７ ｍＲＮＡを低減させるための核酸分子 | |
| JP2023506181A5 (enExample) | ||
| JP2023500661A5 (enExample) | ||
| JP2022527105A5 (enExample) | ||
| JP2023536472A5 (enExample) | ||
| JP2024523363A5 (enExample) | ||
| JP2024544532A (ja) | Ｈｂｖの処置のための医薬組合せ | |
| JP2025039668A (ja) | Ｒｔｅｌ１発現の調節用のオリゴヌクレオチド | |
| JP2024544532A5 (enExample) | ||
| JP2024540537A5 (enExample) | ||
| JP2022515140A5 (enExample) | ||
| JP2024506351A5 (enExample) |